Endocrinology drugs market size to grow by USD 36551.24 Million: Increase in the incidence of endocrine disorders remains key growth driver - Technavio

NEW YORK, Dec. 7, 2022 /PRNewswire/ -- The global endocrinology drugs market size is set to grow by USD 36551.24 million from 2022 to 2027, according to Technavio. The growth momentum of the market will accelerate at a CAGR of 7.82% during the forecast period. This report provides analysis and insights to enable effective decision-making. Download A Sample Report

Endocrinology drugs market - Key Driver and Major Challenge

The increase in the incidence of endocrine disorders is driving the endocrinology drug market growth. The prevalence of endocrine disorders such as diabetes is increasing globally, especially in low and middle-income countries. The incidence of such disorders is high in the aging population. With advances in healthcare technology, the average life expectancy of people has increased considerably across the world. This has resulted in an increase in the aging population worldwide. Thus, the rising incidence of endocrine disorders and the expanding aging population are expected to drive the growth of the global endocrinology drugs market during the forecast period.

The expiring patents of major endocrinology drugs are impeding the endocrinology drug market growth. Endocrinology drugs were available in the market since 1995, and many of the approved drugs available back then are on the verge of expiring. For instance, Lantus, one of the world's most widely prescribed insulin, lost its patent in February 2015. Similarly, NovoLog/NovoRapid's patent expired in 2014. These forthcoming patent expirations paved the way for generic drugs, resulting in the loss of market share by branded drug manufacturers. This is expected to reduce the growth potential in the market over the forecast period.

Technavio has identified key trends, drivers, and challenges, along with competitive analysis to help clients improve their strategies to stay ahead of their competitors. Buy the report to obtain detailed insights about the market.

Major five endocrinology drugs companies

• Acerus Pharmaceuticals Corp. - The company offers endocrinology drugs such as Natesto.
• Bayer AG - The company offers endocrinology drugs such as finerenone.
• Beta Cell NV - The company offers endocrinology drugs such as BetaGraft.
• Eli Lilly and Co. - The company offers endocrinology drugs such as Humatrope.
• Endo International Plc - The company offers endocrinology drugs such as fortesta.

Other key vendors

• Abbott Laboratories
• Ascendis Pharma AS
• Biocon Ltd.
• F. Hoffmann La Roche Ltd.
• GlaxoSmithKline Plc
• Hanmi Pharm Co. Ltd.
• Ipsen Pharma
• Merck & Co. Inc.
• Novartis AG
• Novo Nordisk AS

Get lifetime access to our Technavio Insights! Subscribe to our Basic Plan billed annually at USD 5000

• Diabetes drugs - size and forecast 2022-2027
• HGH - size and forecast 2022-2027
• Thyroid hormone disorders - size and forecast 2022-2027
• Others - size and forecast 2022-2027

• Hospital pharmacies - size and forecast 2022-2027
• Retail pharmacies - size and forecast 2022-2027
• Online pharmacies - size and forecast 2022-2027

• North America - size and forecast 2022-2027
• Europe - size and forecast 2022-2027
• Asia - size and forecast 2022-2027
• Rest of World (ROW) - size and forecast 2022-2027

Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a PDF Sample Report

What are the key data covered in this endocrinology drugs market report?

• CAGR of the market during the forecast period 2023-2027
• Detailed information on factors that will drive the growth of the endocrinology drugs market between 2023 and 2027
• Precise estimation of the endocrinology drugs market size and its contribution to the parent market.
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the endocrinology drugs industry across North America, Europe, Asia, and the Rest of the World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information about vendors
• Comprehensive details of factors that will challenge the growth of endocrinology drugs market vendors

Related Reports

• The biosimilars market is estimated to grow at a CAGR of 23% between 2022 and 2027. The size of the market is forecast to increase by USD 42,227.12 million. The price advantage of biosimilars over biologics is notably driving the market growth, although factors such as market access barriers for biosimilars may impede the market growth.
• The botanical and plant-derived drugs market size is expected to increase by USD 15.89 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 7.25%. The increase in government initiatives is notably driving the botanical and plant-derived drugs market growth, although factors such as low acceptance among physicians may impede the market growth.

1 Executive Summary

• 1.1 Market overview 
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Therapy Area
• Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
• Exhibit 07: Executive Summary – Chart on Incremental Growth
• Exhibit 08: Executive Summary – Data Table on Incremental Growth
• Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem 
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition 
• Exhibit 12: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 13: Market segments

• 3.3 Market size 2022

• 3.4 Market outlook: Forecast for 2022-2027 
• Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

• 4.1 Global endocrinology drugs market 2017 - 2021
• Exhibit 18: Historic Market Size – Data Table on Global endocrinology drugs market 2017 - 2021 ($ million)

• 4.2 Therapy Area Segment Analysis 2017 - 2021
• Exhibit 19: Historic Market Size – Therapy Area Segment 2017 - 2021 ($ million)

• 4.3 Distribution Channel Segment Analysis 2017 - 2021
• Exhibit 20: Historic Market Size – Distribution Channel Segment 2017 - 2021 ($ million)

• 4.4 Geography Segment Analysis 2017 - 2021 
• Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)

• 4.5 Country Segment Analysis 2017 - 2021 
• Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary 
• Exhibit 23: Five forces analysis - Comparison between 2022 and 2027

• 5.2 Bargaining power of buyers 
• Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

• 5.3 Bargaining power of suppliers 
• Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

• 5.4 Threat of new entrants 
• Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027

• 5.5 Threat of substitutes 
• Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027

• 5.6 Threat of rivalry 
• Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027

• 5.7 Market condition 
• Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Therapy Area

• 6.1 Market segments 
• Exhibit 30: Chart on Therapy Area - Market share 2022-2027 (%)
• Exhibit 31: Data Table on Therapy Area - Market share 2022-2027 (%)

• 6.2 Comparison by Therapy Area 
• Exhibit 32: Chart on Comparison by Therapy Area
• Exhibit 33: Data Table on Comparison by Therapy Area

• 6.3 Diabetes drugs - Market size and forecast 2022-2027
• Exhibit 34: Chart on Diabetes drugs - Market size and forecast 2022-2027 ($ million)
• Exhibit 35: Data Table on Diabetes drugs - Market size and forecast 2022-2027 ($ million)
• Exhibit 36: Chart on Diabetes drugs - Year-over-year growth 2022-2027 (%)
• Exhibit 37: Data Table on Diabetes drugs - Year-over-year growth 2022-2027 (%)

• 6.4 hGH - Market size and forecast 2022-2027
• Exhibit 38: Chart on hGH - Market size and forecast 2022-2027 ($ million)
• Exhibit 39: Data Table on hGH - Market size and forecast 2022-2027 ($ million)
• Exhibit 40: Chart on hGH - Year-over-year growth 2022-2027 (%)
• Exhibit 41: Data Table on hGH - Year-over-year growth 2022-2027 (%)

• 6.5 Thyroid hormone disorders - Market size and forecast 2022-2027 
• Exhibit 42: Chart on Thyroid hormone disorders - Market size and forecast 2022-2027 ($ million)
• Exhibit 43: Data Table on Thyroid hormone disorders - Market size and forecast 2022-2027 ($ million)
• Exhibit 44: Chart on Thyroid hormone disorders - Year-over-year growth 2022-2027 (%)
• Exhibit 45: Data Table on Thyroid hormone disorders - Year-over-year growth 2022-2027 (%)

• 6.6 Others - Market size and forecast 2022-2027
• Exhibit 46: Chart on Others - Market size and forecast 2022-2027 ($ million)
• Exhibit 47: Data Table on Others - Market size and forecast 2022-2027 ($ million)
• Exhibit 48: Chart on Others - Year-over-year growth 2022-2027 (%)
• Exhibit 49: Data Table on Others - Year-over-year growth 2022-2027 (%)

• 6.7 Market opportunity by Therapy Area 
• Exhibit 50: Market opportunity by Therapy Area ($ million)

7 Market Segmentation by Distribution Channel

• 7.1 Market segments 
• Exhibit 51: Chart on Distribution Channel - Market share 2022-2027 (%)
• Exhibit 52: Data Table on Distribution Channel - Market share 2022-2027 (%)

• 7.2 Comparison by Distribution Channel 
• Exhibit 53: Chart on Comparison by Distribution Channel
• Exhibit 54: Data Table on Comparison by Distribution Channel

• 7.3 Hospital pharmacies - Market size and forecast 2022-2027
• Exhibit 55: Chart on Hospital pharmacies - Market size and forecast 2022-2027 ($ million)
• Exhibit 56: Data Table on Hospital pharmacies - Market size and forecast 2022-2027 ($ million)
• Exhibit 57: Chart on Hospital pharmacies - Year-over-year growth 2022-2027 (%)
• Exhibit 58: Data Table on Hospital pharmacies - Year-over-year growth 2022-2027 (%)

• 7.4 Retail pharmacies - Market size and forecast 2022-2027
• Exhibit 59: Chart on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
• Exhibit 60: Data Table on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
• Exhibit 61: Chart on Retail pharmacies - Year-over-year growth 2022-2027 (%)
• Exhibit 62: Data Table on Retail pharmacies - Year-over-year growth 2022-2027 (%)

• 7.5 Online pharmacies - Market size and forecast 2022-2027
• Exhibit 63: Chart on Online pharmacies - Market size and forecast 2022-2027 ($ million)
• Exhibit 64: Data Table on Online pharmacies - Market size and forecast 2022-2027 ($ million)
• Exhibit 65: Chart on Online pharmacies - Year-over-year growth 2022-2027 (%)
• Exhibit 66: Data Table on Online pharmacies - Year-over-year growth 2022-2027 (%)

• 7.6 Market opportunity by Distribution Channel
• Exhibit 67: Market opportunity by Distribution Channel ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview 
• Exhibit 68: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation 
• Exhibit 69: Chart on Market share by geography 2022-2027 (%)
• Exhibit 70: Data Table on Market share by geography 2022-2027 (%)

• 9.2 Geographic comparison 
• Exhibit 71: Chart on Geographic comparison
• Exhibit 72: Data Table on Geographic comparison

• 9.3 North America - Market size and forecast 2022-2027
• Exhibit 73: Chart on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 74: Data Table on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 75: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibit 76: Data Table on North America - Year-over-year growth 2022-2027 (%)

• 9.4 Europe - Market size and forecast 2022-2027
• Exhibit 77: Chart on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 78: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 79: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibit 80: Data Table on Europe - Year-over-year growth 2022-2027 (%)

• 9.5 Asia - Market size and forecast 2022-2027
• Exhibit 81: Chart on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 82: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 83: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibit 84: Data Table on Asia - Year-over-year growth 2022-2027 (%)

• 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
• Exhibit 85: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 86: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 87: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibit 88: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)

• 9.7 US - Market size and forecast 2022-2027
• Exhibit 89: Chart on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 90: Data Table on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 91: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibit 92: Data Table on US - Year-over-year growth 2022-2027 (%)

• 9.8 UK - Market size and forecast 2022-2027
• Exhibit 93: Chart on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 94: Data Table on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 95: Chart on UK - Year-over-year growth 2022-2027 (%)
• Exhibit 96: Data Table on UK - Year-over-year growth 2022-2027 (%)

• 9.9 Germany - Market size and forecast 2022-2027
• Exhibit 97: Chart on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 98: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 99: Chart on Germany - Year-over-year growth 2022-2027 (%)
• Exhibit 100: Data Table on Germany - Year-over-year growth 2022-2027 (%)

• 9.10 China - Market size and forecast 2022-2027
• Exhibit 101: Chart on China - Market size and forecast 2022-2027 ($ million)
• Exhibit 102: Data Table on China - Market size and forecast 2022-2027 ($ million)
• Exhibit 103: Chart on China - Year-over-year growth 2022-2027 (%)
• Exhibit 104: Data Table on China - Year-over-year growth 2022-2027 (%)

• 9.11 Canada - Market size and forecast 2022-2027
• Exhibit 105: Chart on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibit 106: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibit 107: Chart on Canada - Year-over-year growth 2022-2027 (%)
• Exhibit 108: Data Table on Canada - Year-over-year growth 2022-2027 (%)

• 9.12 Market opportunity by geography 
• Exhibit 109: Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers

• 10.2 Market challenges

• 10.3 Impact of drivers and challenges 
• Exhibit 110: Impact of drivers and challenges in 2022 and 2027

• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview

• 11.2 Vendor landscape 
• Exhibit 111: Overview on Criticality of inputs and Factors of differentiation

• 11.3 Landscape disruption 
• Exhibit 112: Overview on factors of disruption

• 11.4 Industry risks 
• Exhibit 113: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered 
• Exhibit 114: Vendors covered

• 12.2 Market positioning of vendors 
• Exhibit 115: Matrix on vendor position and classification

• 12.3 Acerus Pharmaceuticals Corp. 
• Exhibit 116: Acerus Pharmaceuticals Corp. - Overview
• Exhibit 117: Acerus Pharmaceuticals Corp. - Product / Service
• Exhibit 118: Acerus Pharmaceuticals Corp. - Key offerings

• 12.4 Bayer AG 
• Exhibit 119: Bayer AG - Overview
• Exhibit 120: Bayer AG - Business segments
• Exhibit 121: Bayer AG - Key offerings
• Exhibit 122: Bayer AG - Segment focus

• 12.5 Beta Cell NV 
• Exhibit 123: Beta Cell NV - Overview
• Exhibit 124: Beta Cell NV - Product / Service
• Exhibit 125: Beta Cell NV - Key offerings

• 12.6 Eli Lilly and Co. 
• Exhibit 126: Eli Lilly and Co. - Overview
• Exhibit 127: Eli Lilly and Co. - Product / Service
• Exhibit 128: Eli Lilly and Co. - Key offerings

• 12.7 Endo International Plc 
• Exhibit 129: Endo International Plc - Overview
• Exhibit 130: Endo International Plc - Business segments
• Exhibit 131: Endo International Plc - Key news
• Exhibit 132: Endo International Plc - Key offerings
• Exhibit 133: Endo International Plc - Segment focus

• 12.8 F. Hoffmann La Roche Ltd. 
• Exhibit 134: F. Hoffmann La Roche Ltd. - Overview
• Exhibit 135: F. Hoffmann La Roche Ltd. - Business segments
• Exhibit 136: F. Hoffmann La Roche Ltd. - Key news
• Exhibit 137: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibit 138: F. Hoffmann La Roche Ltd. - Segment focus

• 12.9 GlaxoSmithKline Plc 
• Exhibit 139: GlaxoSmithKline Plc - Overview
• Exhibit 140: GlaxoSmithKline Plc - Business segments
• Exhibit 141: GlaxoSmithKline Plc - Key offerings
• Exhibit 142: GlaxoSmithKline Plc - Segment focus

• 12.10 Hanmi Pharm Co. Ltd. 
• Exhibit 143: Hanmi Pharm Co. Ltd. - Overview
• Exhibit 144: Hanmi Pharm Co. Ltd. - Product / Service
• Exhibit 145: Hanmi Pharm Co. Ltd. - Key offerings

• 12.11 Ipsen Pharma 
• Exhibit 146: Ipsen Pharma - Overview
• Exhibit 147: Ipsen Pharma - Business segments
• Exhibit 148: Ipsen Pharma - Key offerings
• Exhibit 149: Ipsen Pharma - Segment focus

• 12.12 Merck and Co. Inc. 
• Exhibit 150: Merck and Co. Inc. - Overview
• Exhibit 151: Merck and Co. Inc. - Business segments
• Exhibit 152: Merck and Co. Inc. - Key news
• Exhibit 153: Merck and Co. Inc. - Key offerings
• Exhibit 154: Merck and Co. Inc. - Segment focus

• 12.13 Novartis AG 
• Exhibit 155: Novartis AG - Overview
• Exhibit 156: Novartis AG - Business segments
• Exhibit 157: Novartis AG - Key offerings
• Exhibit 158: Novartis AG - Segment focus

• 12.14 Novo Nordisk AS 
• Exhibit 159: Novo Nordisk AS - Overview
• Exhibit 160: Novo Nordisk AS - Business segments
• Exhibit 161: Novo Nordisk AS - Key offerings
• Exhibit 162: Novo Nordisk AS - Segment focus

• 12.15 Pfizer Inc. 
• Exhibit 163: Pfizer Inc. - Overview
• Exhibit 164: Pfizer Inc. - Product / Service
• Exhibit 165: Pfizer Inc. - Key news
• Exhibit 166: Pfizer Inc. - Key offerings

• 12.16 Sanofi SA 
• Exhibit 167: Sanofi SA - Overview
• Exhibit 168: Sanofi SA - Business segments
• Exhibit 169: Sanofi SA - Key news
• Exhibit 170: Sanofi SA - Key offerings
• Exhibit 171: Sanofi SA - Segment focus

• 12.17 Takeda Pharmaceutical Co. Ltd. 
• Exhibit 172: Takeda Pharmaceutical Co. Ltd. - Overview
• Exhibit 173: Takeda Pharmaceutical Co. Ltd. - Product / Service
• Exhibit 174: Takeda Pharmaceutical Co. Ltd. - Key news
• Exhibit 175: Takeda Pharmaceutical Co. Ltd. - Key offerings

13 Appendix

• 13.1 Scope of the report

• 13.2 Inclusions and exclusions checklist 
• Exhibit 176: Inclusions checklist
• Exhibit 177: Exclusions checklist

• 13.3 Currency conversion rates for US$ 
• Exhibit 178: Currency conversion rates for US$

• 13.4 Research methodology 
• Exhibit 179: Research methodology
• Exhibit 180: Validation techniques employed for market sizing
• Exhibit 181: Information sources

• 13.5 List of abbreviations 
• Exhibit 182: List of abbreviations

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio